KR101106487B1 - A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 - Google Patents
A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 Download PDFInfo
- Publication number
- KR101106487B1 KR101106487B1 KR1020110072609A KR20110072609A KR101106487B1 KR 101106487 B1 KR101106487 B1 KR 101106487B1 KR 1020110072609 A KR1020110072609 A KR 1020110072609A KR 20110072609 A KR20110072609 A KR 20110072609A KR 101106487 B1 KR101106487 B1 KR 101106487B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- ginsenoside
- acid
- ginseng extract
- extract
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 70
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 title claims abstract description 13
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 title claims description 8
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title description 13
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 title 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000012141 concentrate Substances 0.000 claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 10
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001630 malic acid Substances 0.000 claims abstract description 8
- 235000011090 malic acid Nutrition 0.000 claims abstract description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 5
- 239000011975 tartaric acid Substances 0.000 claims abstract description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 4
- 239000001384 succinic acid Substances 0.000 claims abstract description 4
- 235000011044 succinic acid Nutrition 0.000 claims abstract description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 17
- 150000007524 organic acids Chemical class 0.000 claims description 15
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000005728 strengthening Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 claims 1
- 229930182490 saponin Natural products 0.000 abstract description 19
- 150000007949 saponins Chemical class 0.000 abstract description 19
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 8
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 abstract 4
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 abstract 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract 2
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 abstract 2
- 241000208340 Araliaceae Species 0.000 description 28
- 235000008434 ginseng Nutrition 0.000 description 28
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 27
- 235000003140 Panax quinquefolius Nutrition 0.000 description 27
- 235000017709 saponins Nutrition 0.000 description 18
- 239000002994 raw material Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 8
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 7
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 4
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- HLLSOEKIMZEGFV-UHFFFAOYSA-N 4-(dibutylsulfamoyl)benzoic acid Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 HLLSOEKIMZEGFV-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- -1 nitrogen-containing compound Chemical class 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 인삼사포닌 성분이 강화된 홍삼농축액을 제조하는 방법에 관한 것이며, 보다 구체적으로는 홍삼액으로 진세노사이드 Rg3 및 Rh2 성분이 고농도로 함유된 홍삼농축액을 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing a red ginseng concentrate enriched with ginseng saponin components, and more particularly, to a method for preparing a red ginseng concentrate containing high concentrations of ginsenosides Rg 3 and Rh 2 as red ginseng solution.
인삼은 식물학적으로 오가과(Araliaceae)의 인삼속(Panax)에 속하는 식물로서, 동양에서는 오래전부터 효능 및 유효성이 잘 알려져 온 한약재이다.Ginseng is botanically belonging to the genus Panax of the Araliaceae, a herb that has long been known for its efficacy and effectiveness in the Orient.
근래 들어 인삼의 약리효능 연구의 과학적 진보에 따라 인삼으로부터 특유의 진세노사이드 성분을 분리하고, 그 화학구조를 밝히는 한편, 인삼의 유효성분과 약리효능을 구명함에 따라 인삼의 개별 사포닌마다 그 약리효능이 각각 다르고 새로운 효능이 속속들이 밝혀짐으로써 특정성분의 사포닌을 강화시킨 기능성 제품을 효율적이고 경제성 있게 제조하기 위한 인삼의 가공 및 제조방법과 관련된 기술이 개발되고 있으며, 이러한 기술들이 각광을 받고 있다.In recent years, according to scientific advances in researching the pharmacological efficacy of ginseng, the distinctive ginsenosides of ginseng are separated from the ginseng, their chemical structures are revealed, and the active ingredients and pharmacological effects of ginseng are investigated. As different and new effects are revealed one after another, technologies related to ginseng processing and manufacturing methods for efficiently and economically manufacturing functional products enhanced with saponins of specific ingredients have been developed, and these technologies have been in the spotlight.
인삼에 함유된 특정성분의 사포닌을 강화시킨 기술과 관련하여 고전적인 방법으로 구증구포에 의한 흑삼제조방법이 알려져 있으며, 홍삼농축액 및 추출액을 고온 고압처리하는 열처리에 의한 방법이 있는데, 고전적인 흑삼제조의 방법은 제조공정에 따른 시간이 너무 긴 단점이 있고, 고온고압처리 방법은 제조공정에 따른 시간은 단축할 수 있으나 고온고압에 의한 에너지 소비에 따른 비용이 증가하고, 공정 안정성이 낮은 단점이 있다.A method of producing black ginseng by vesicles is known as a classical method in relation to the technology of strengthening saponin of a specific ingredient contained in ginseng, and there is a method by heat treatment of red ginseng concentrate and extract at high temperature and high pressure. The method has a disadvantage that the time according to the manufacturing process is too long, and the high temperature and high pressure treatment method can shorten the time according to the manufacturing process, but the cost of energy consumption increases due to the high temperature and high pressure, and the process stability is low. .
그리고 미생물(유산균)에 의한 방법, 산 및 효소에 의한 가수분해방법 등이 있으며, 미생물(유산균)에 의한 방법은 특정사포닌을 선택적으로 강화시킬 수 있는 장점은 있으나, 유산균의 선택과 배양하는 기술이 어렵고, 공정이 복잡하고 관리하기가 어렵다는 단점이 있으며, 상기 가수분해방법은 산의 종류나 효소의 종류에 따라서 특정사포닌의 선택성이나 변환효율이 차이가 나고, 일반적으로 미생물에 의한 방법보다 선택성이나 변환효율이 다소 떨어진다는 것이 단점이 있지만, 공정이 간단하여 생산단가를 현저히 낮출 수 있는 장점이 있고, 특히, 특정 사포닌 변환에 적합한 산이나 효소의 선택과 공정의 최적조건을 개발한다면 산업경쟁력이 가장 큰 기술이다.And microbial (lactic acid bacteria) method, acid and enzyme hydrolysis method, etc. The microorganism (lactic acid bacteria) method has the advantage that can selectively strengthen the specific saponin, but the selection and culture technology of lactic acid bacteria It is difficult, the process is complicated and difficult to manage, the hydrolysis method is different in the selectivity or conversion efficiency of a particular saponin according to the type of acid or enzyme, generally selectivity or conversion than the method by the microorganism Although the disadvantage is that the efficiency is rather low, the process is simple and the production cost can be significantly reduced. In particular, if the selection of an acid or enzyme suitable for a specific saponin conversion and the development of the optimum conditions of the process are the most competitive Technology.
또한, 인삼에 함유된 특정성분의 사포닌을 강화시킨 선행기술로 예를 들면, 대한민국 공개특허공보 공개번호 10-2010-0098208호에는 인삼을 9회 증숙하고, 9회 건조 즉, 증숙과 건조를 9회 반복하는 과정에서 1회 및 6회차의 증숙공정을 상압 및 5~15기압의 압력조건하에서 수행하여 Rg3 및 Rh2의 함량이 증가된 흑삼의 제조방법을 개시하고 있으며, 이는 이른바 구증구포(九蒸九曝)하여 흑삼을 제조하는 방법을 이용하여 고압 하에서 열처리하는 기술로서, 고온고압조건에서 30일 이상의 긴 공정시간을 필요로 하기 때문에 비경제적 단점이 있으며, 또 대한민국 공개특허공보 공개번호 10-2011-0052940호에는 인삼의 진세노사이드 Rb1함유 주정 추출물을 물 및 초산의 혼합물과 반응시킨 다음 정제하여 진세노사이드 Rg3가 강화된 인삼 추출물 분획을 제조하는 방법을 개시하고 있으며, 이는 반응 시에 초산 사용량이 반응액 부피 대비 25% 정도 사용하기 때문에 제품품질이 저하될 우려가 있을 뿐만 아니라 진세노사이드 Rg3만을 강화시킬 수 있고, 또한, 공정상에 다이아이온 HP-20 칼럼 등 정제방법을 사용하기 때문에 공정이 복잡한 단점을 가지고 있다.In addition, as a prior art for strengthening the saponin of a specific ingredient contained in ginseng, for example, Korean Patent Laid-Open Publication No. 10-2010-0098208 No. 9 ginseng steamed nine times, 9 times drying, that is, steaming and drying 9 iterations to perform the steaming step of once, and 6 Recurrence under pressure conditions of atmospheric pressure and 5 to 15 atm in the process of Rg 3 And a method of manufacturing black ginseng with an increased content of Rh 2 , which is a technique of heat treatment under high pressure using a method of producing black ginseng by soaking agglomerate, and at least 30 days under high temperature and high pressure conditions. There is an uneconomical disadvantage because it requires a long process time, and Korean Patent Laid-Open Publication No. 10-2011-0052940 discloses ginsenoside Rb 1- containing alcohol extract of ginseng reacted with a mixture of water and acetic acid and then purified A method for preparing a ginseng extract fraction fortified with ginsenoside Rg 3 is disclosed. In this case, acetic acid is used at a rate of about 25% of the volume of the reaction solution, resulting in deterioration of product quality as well as ginsenosides. Only Rg 3 can be strengthened, and the process uses complicated purification methods such as a DIION HP-20 column, which adds complexity. ought.
또, 대한민국 공개특허공보 공개번호 10-2010-0111457호에는 백삼으로부터 백삼 추출물을 제조하고, 상기 백삼 추출물을 산가수분해 열처리하여 백삼 추출물로부터 Rg3의 전환을 유도함으로써 진세노사이드 Rg3를 함유한 산가수분해 백삼 추출물의 제조방법을 개시하고 있으며, 이는 진세노사이드 Rg3 함유량이 증가된 산가수분해 백삼 추출물이 얻어지고 있으나, 시트르산(citric acid)을 이용하여 PD(panaxadiol)계 사포닌을 산가수분해하여 Rg3를 강화시키는 방법으로서, 원료의 전처리공정에서 백삼추출액을 추출하여 고형분이 60% 이상으로 고농축 시킨 후, 80% 주정으로 불순물을 침전시키는 공정이 추가되어 있고, 다시 이로부터 얻어진 추출액을 10배 희석하여 산가수분해반응에 사용하므로 원료인 백삼추출물을 얻는 공정이 복잡한 것이 단점이다.In addition, Korean Unexamined Patent Publication No. 10-2010-0111457 prepared ginseng extract from white ginseng, and the acid hydrolysis heat treatment of the white ginseng extract to induce the conversion of Rg 3 from white ginseng extract containing ginsenoside Rg 3 A method for preparing an acid hydrolyzed white ginseng extract is disclosed. An acid hydrolyzed white ginseng extract having an increased content of ginsenoside Rg 3 has been obtained, but acid hydrolyzed PD (panaxadiol) -based saponins using citric acid. As a method of decomposing and strengthening Rg 3 , a white ginseng extract is extracted in the pretreatment step of the raw material, the solid content is concentrated to 60% or more, and then impurities are precipitated at 80% alcohol. Diluted 10 times and used for acid hydrolysis reaction is a complicated process to obtain white ginseng extract as a raw material.
상기한 바와 같이 인삼에는 사포닌이 일반적으로 약 33종 함유되어 있으며, 함량으로는 4% ~ 6% 정도가 포함되어 있는데, 특정 사포닌이 강화된 제품을 생산하기 위하여 보다 단순한 공정에서 효율적으로 제조할 수 있는 기술을 개발하는 것이 향후 기술진보에 바람직할 것이다.As mentioned above, ginseng generally contains about 33 kinds of saponins, and contains 4% to 6% by content, and can be efficiently manufactured in a simpler process in order to produce a product enhanced with a specific saponin. Developing such technology would be desirable for future technological progress.
본 발명은 상기한 종래기술 및 선행기술들이 갖는 제법 상 공정이 번거롭고, 비용이 다소 많이 소요될 수 있는 단점을 개선하여 보다 간편한 방법에 의해서 특정 사포닌 변환율이 높을 뿐만 아니라 진세노사이드 Rg3 및 Rh2가 동시에 강화된 홍삼농축액을 제조하는 방법을 제공하는 것을 목적으로 하는 것이며, 보다 구체적으로는 홍삼추출액을 산가수분해하는 방법에 의해 홍삼추출액에 존재하는 진세노사이드 성분 중에서 암예방, 항암제 작용이 뛰어난 진세노사이드 Rg3 및 Rh2 성분을 동시에 강화시킨 홍삼농축액을 제조하는 방법의 제공을 목적으로 하는 것이다.The present invention improves the drawbacks of the above-described prior art and prior art processes, which may be cumbersome and costly, and thus the specific saponin conversion is not only high, but also ginsenosides Rg 3 and Rh 2 are added by a simpler method. At the same time, an object of the present invention is to provide a method for producing an enhanced red ginseng concentrate, and more specifically, a ginsenoside component present in the red ginseng extract by acid hydrolysis of the red ginseng extract, which has excellent cancer prevention and anticancer activity. It is an object of the present invention to provide a method for producing a red ginseng concentrate having the cenoside Rg 3 and Rh 2 components simultaneously enhanced.
본 발명에 따른 홍삼농축액을 제조하는 방법의 해결수단으로는 유기산을 홍삼추출액과 혼합하여 가수분해 반응시키는 것에 의해 진세노사이드 Rg3 및 Rh2 성분을 동시에 강화시킨 홍삼농축액을 제조하는 것으로 이루어지며, 보다 상세하게는 사과산(malic acid), 포도산(tartaric acid) 및 호박산(succinic acid)으로부터 선택되는 유기산을 홍삼추출액과 혼합하여 가수분해 반응시키는 것에 의해 진세노사이드 Rg3 및 Rh2 성분을 동시에 강화시킨 홍삼농축액을 제조하는 것으로 이루어진다.As a solution of the method for producing the red ginseng concentrate according to the present invention consists of preparing a red ginseng concentrate to strengthen the ginsenoside Rg 3 and Rh 2 components by the hydrolysis reaction by mixing the organic acid with the red ginseng extract, More specifically, the ginsenoside Rg 3 and Rh 2 components are simultaneously strengthened by mixing the organic acid selected from malic acid, tartaric acid, and succinic acid with the red ginseng extract. It consists of preparing the prepared red ginseng concentrate.
또 본 발명에 따른 홍삼농축액의 제조를 위하여 원료로 선택하는 홍삼추출액은 본 발명이 속하는 기술분야에서 잘 알려진 추출방법에 따라 제조되는 홍삼추출액을 사용하며, 특별히 제한하는 것은 아니며, 구체적으로는 건조홍삼을 추출용매인 순도 30% ~ 70%의 주정으로 70℃ ~ 90℃에서 4차까지 추출 농축하여 제조된 것을 이용하며, 구체적으로는 진세노사이드 Rb1의 함량이 24mg/g이고 고형분이 70중량%인 홍삼추출액을 사용한다.In addition, the red ginseng extract selected as a raw material for the preparation of the red ginseng concentrate according to the present invention uses a red ginseng extract prepared according to well-known extraction methods in the art to which the present invention belongs, and is not particularly limited, specifically dry red ginseng The extract was prepared by extracting and concentrating the fourth solvent at 70 ° C. to 90 ° C. with an alcohol having a purity of 30% to 70%. Specifically, the content of ginsenoside Rb 1 is 24 mg / g and the solid content is 70 weight. Use red ginseng extract which is%.
일반적으로 인삼은 사포닌 3 ~ 6%, 함질소화합물 12 ~ 15%, 지용성 성분 1 ~ 2%, 탄수화물계 50 ~ 60% 및 기타 4 ~ 6% 정도로 구성되어 있으며, 특히, 상기 구성성분 중 인삼의 종(種)에 따른 특이적인 성분은 생리활성물질이며, 사포닌의 일종인 진세노사이드(ginsenoside)가 약 3 ~ 6% 함유되어 있고, 진세노사이드(ginsenoside)는 분자구조에 따라 파낙사디올계(Panaxadiol: PD)와 파낙사트리올계(Panaxatriol: PT), 올레아난계(Oleanane)로 나뉘며 약 33종이 보고되고 있다[최신고려인삼, 한국인삼연초연구원, 1996년]. 상기와 관련된 인삼의 상세한 구성성분은 [표 1]에 나타내었다.In general, ginseng is composed of 3-6% saponin, 12-15% nitrogen-containing compound, 1-2% fat-soluble component, 50-60% carbohydrate-based, and other 4-6%. Specific components according to species are physiologically active substances, containing about 3-6% of ginsenoside, a kind of saponin, and ginsenosides based on molecular structure (Panaxadiol: PD), Panaxatriol (PT), Oleanan (Oleanane), and about 33 species have been reported [Latest Korea Ginseng, Korea Ginseng and Tobacco Research Institute, 1996]. Detailed components of ginseng related to the above are shown in [Table 1].
그리고 백삼제품과 홍삼제품은 그 제조방법에 차이가 있으며, 진세노사이드 Rg3의 함량이 백삼제품은 0.003 mg/g, 홍삼제품은 0.2 mg/g 함유하고 있어 백삼제품에 비하여 홍삼제품의 진세노사이드 Rg3의 함량이 70배 이상 높은 함량을 나타내며, 또 진세노사이드 Rh2의 함량 역시 백삼제품이 0mg/g, 홍삼제품이 0.01 mg/g 함유하고 있어 백삼제품에 비하여 홍삼제품의 진세노사이드 Rh2의 함량이 100배 정도 높은 함량을 나타내고 있다{Chem. Pharm. Bull. 45, 1039~1045(1997), Chem. Pharm. Bull. 46, 647~654(1998), Chem. Pharm. Bull. 49, 1452~1456(2001)}. In addition, white ginseng products and red ginseng products have different manufacturing methods, and ginsenoside Rg 3 contains 0.003 mg / g of white ginseng products and 0.2 mg / g of red ginseng products. The content of side Rg 3 is 70 times higher, and the content of ginsenoside Rh 2 also contains 0mg / g of white ginseng products and 0.01 mg / g of red ginseng products. The content of Rh 2 is about 100 times higher {Chem. Pharm. Bull. 45, 1039-1045 (1997), Chem. Pharm. Bull. 46, 647-654 (1998), Chem. Pharm. Bull. 49, 1452-1456 (2001).
인삼의 약리효능으로는 중추신경계질환, 항불안, 신경계, 마약중독해독 효능, 혈관작용, 알콜해독, 지질대사와 피로회복, 항당뇨, 고지혈증, 항바이러스, 면역증강, 성기능 개선, 항암 및 암예방 효능 등이 있으며, 특히, 진세노사이드 Rb1으로 대표되는 panaxadiol(PD)계 사포닌은 중추신경에 대한 억제작용을 나타내어 정신안정, 신경이완, 진통, 항암, 항경련, 혈압강하 작용 등을 나타내며, 진세노사이드 Rg1으로 대표되는 panaxatriol(PT)계 사포닌은 중추신경에 대해 흥분적으로 작용하여, 항피로작용을 나타내는 것으로 알려지고, 더욱이, 개별 사포닌마다 그 약리효능이 각각 다르고 새로운 효능을 나타내는 것으로 보고되어 있으며. 주요 사포닌 성분의 약리효과를 아래 [표 2]에 나타내었다.The pharmacological effects of ginseng include central nervous system disease, anti-anxiety, nervous system, drug addiction, vascular effect, alcohol detoxification, lipid metabolism and fatigue, antidiabetic, hyperlipidemia, antiviral, immune enhancement, sexual function improvement, anticancer and cancer prevention In particular, panaxadiol (PD) -based saponin represented by ginsenoside Rb 1 has an inhibitory effect on the central nervous system, and exhibits mental stability, nerve relaxation, analgesic, anticancer, anticonvulsion, blood pressure lowering action, Panaxatriol (PT) -based saponins represented by ginsenoside Rg 1 are known to exert an anti-fatigue effect on the central nervous system. Moreover, the pharmacological effects of each saponin are different and show new efficacy. Reported. Pharmacological effects of the main saponin components are shown in Table 2 below.
본 발명의 특징 중 하나는 상기 [표 2]에 나타나는 바와 같이 항암, 암치료, 항암제 독성 감소, 면역증진, 혈전병 예방 등에 특히 효능이 우수한 Rg3 및 Rh2와 같은 특정성분의 진세노사이드를 동시에 강화시키기 위하여 상기 백삼제품보다 유리한 조건을 나타내는 홍삼추출액을 원료성분으로 사용하여 Rg3 및 Rh2를 동시에 강화시킨 홍삼농축액을 제조하는 것을 특징으로 하는 것이다.One of the features of the invention The table 2 anti-cancer, cancer, chemotherapy toxicity reduction, excellent efficacy, particularly immune enhancement or the like, prevention of thrombotic disease Rg, as shown in 3 In order to simultaneously strengthen the ginsenosides of a specific component such as Rh 2 and Rg 3 using red ginseng extract which shows favorable conditions than the white ginseng product, And it is characterized in that to produce a red ginseng concentrate fortified at the same time Rh 2 .
본 발명에 따른 또 하나의 특징은 인체에 유익한 유기산을 이용하여 가수분해시킴으로써, 정제를 위한 정제수의 부가적인 사용 및 제거에 따른 과정이 필요 없으며, 또 폐액이 전혀 발생되지 않으므로 효율적이고 단순화된 공정에 의해 Rg3 및 Rh2 성분을 동시에 고농도로 강화시킨 홍삼농축액을 제조하는 것을 특징으로 하는 것이다.Another feature of the present invention is that by hydrolyzing with organic acids beneficial to the human body, there is no need for additional use and removal of purified water for purification, and no waste solution is generated, resulting in an efficient and simplified process. By the Rg 3 and Rh 2 components at the same time to prepare a red ginseng concentrate to the high concentration.
그리고 본 발명과 같은 Rg3와 Rh2의 진세노사이드로 변환하는 반응은 아래 [반응식 1]에서와 같이, 대표적인 PD계 사포닌인 진세노사이드 Rb1의 화학구조에서 비당부분(aglycone)의 골격구조에 에테르(ether)가 결합되어 있는 당류인 글루코스(glucose)가 열처리방법, 산 및 효소에 의한 가수분해 방법, 미생물에 의한 방법 등에 의하여 분해되어 떨어져 나가면서 Rg3와 Rh2의 진세노사이드로 변환되어진다[최신고려인삼연구, 고려인삼학회, 2007].And the reaction to convert ginsenosides of Rg 3 and Rh 2 as in the present invention is the skeletal structure of the aglycone in the chemical structure of ginsenoside Rb 1 which is a typical PD-based saponin Glucose, a saccharide with ether attached to it, is decomposed and decomposed into ginsenosides of Rg 3 and Rh 2 as it is decomposed and separated by heat treatment, hydrolysis by acid and enzyme, and microbial method. [Recent Review of Korean Ginseng Research, Korea Ginseng Society, 2007].
[반응식1][Scheme 1]
상기 본 발명에 따른 가수분해 반응조건으로는 대기압 상태에서 90℃ 내지 95℃의 온도에서 3시간 내지 48시간 반응시키며, 24 ~ 48시간 반응시키는 것이 보다 바람직하다. 또 반응에 사용된 유기산의 첨가량은 원료 홍삼추출액에 대하여 1중량% 내지 5중량%의 비율로 첨가하는 것이 바람직하다. As the hydrolysis reaction conditions according to the present invention, the reaction is carried out at a temperature of 90 ° C. to 95 ° C. for 3 hours to 48 hours at atmospheric pressure, and more preferably 24 to 48 hours. The amount of the organic acid used in the reaction is preferably added in a ratio of 1% by weight to 5% by weight based on the raw red ginseng extract.
상기한 본 발명에 따른 홍삼농축액 제조방법은 항암, 암치료, 항암제 독성 감소, 암예방, 면역증진 및 혈전병 예방에 특히 효능이 우수한 Rg3 및 Rh2 성분을 동시에 강화시킨 홍삼농축액을 제공하는 것이므로 본 발명의 홍삼농축액은 암치료, 암예방, 면역증진 등에 보다 우수한 효능을 나타내는 효과가 있으며, 또한, 백삼보다 약리효능이 더 뛰어난 홍삼추출액을 이용하면서 인체에 유익한 유기산을 이용하여 가수분해시킴으로써, 정제를 위한 정제수의 부가적인 사용 및 제거에 따른 과정이 필요 없으며, 또 폐액이 전혀 발생되지 않으므로 효율적이고 단순화된 공정에 의해 Rg3 및 Rh2 성분을 동시에 고농도로 강화시킨 홍삼농축액을 제조하는 것을 특징으로 하는 것이다.Since the red ginseng concentrate production method according to the present invention is to provide a red ginseng concentrate at the same time strengthening the Rg 3 and Rh 2 components that are particularly effective in anti-cancer, cancer treatment, anti-cancer toxicity reduction, cancer prevention, immune enhancement and prevention of thrombosis. The red ginseng concentrate of the present invention has the effect of showing better efficacy, such as cancer treatment, cancer prevention, immune enhancement, and also, by using a red ginseng extract having a more pharmacological effect than white ginseng by hydrolysis using an organic acid beneficial to the human body, There is no need for additional use and removal of purified water, and since no waste solution is generated, red ginseng concentrate is prepared by strengthening the Rg 3 and Rh 2 components at a high concentration simultaneously by an efficient and simplified process. It is.
도 1은 표준물질, 본 발명에 사용된 원료인 홍삼추출액 및 본 발명에 따라 제조된 홍삼농축액 중의 Rg3 및 Rh2 함량에 대한 HPLC 데이터이다.1 is HPLC data on Rg 3 and Rh 2 contents in a standard material, red ginseng extract which is a raw material used in the present invention, and red ginseng concentrate prepared according to the present invention.
이하에서는 실시예를 통하여 본 발명에 따른 홍삼농축액의 제조방법을 보다 구체적으로 설명하기로 하겠으며, 하기 실시예가 본 발명을 한정하는 것은 아니다.Hereinafter, the preparation method of the red ginseng concentrate according to the present invention will be described in more detail with reference to Examples, but the following Examples do not limit the present invention.
또 본 발명의 실시예에서는 충남 금산군 소재 대동고려삼 주식회사(본 발명의 출원인)에서 제조한 원료 홍삼추출액을 사용하였으며, 특히, 본 발명의 실시예에서 사용하는 원료인 홍삼추출액은 상기 대동고려삼 주식회사에서 4 ~ 10 톤/월 정도 대량 생산하고 있기 때문에 원료공급을 위한 추가적인 공정이 필요 없어 생산단가를 현저히 낮출 수 있다.
In addition, the embodiment of the present invention used a raw red ginseng extract prepared by Daedong Goryeo Co., Ltd. (applicant of the present invention) in Geumsan-gun, Chungnam, in particular, the red ginseng extract used in the embodiment of the present invention is 4 in the Daedong Goryeo Co., Ltd. Since it is mass producing ~ 10 tons / month, no additional process for raw material supply is required, which can significantly lower production costs.
<원료 홍삼추출액의 제조><Preparation of Raw Red Ginseng Extract>
건조홍삼을 추출용기에 옮기고 순도 70% 주정을 원료부피 대비 8배수 투여하여 75℃에서 24시간 1차 추출하고 농축한 다음, 다시 순도 50% 주정을 원료 부피대비 8배수 투여하여 80℃에서 24시간 2차 추출하고 농축한 다음, 다시 순도 30% 주정을 원료 부피대비 8배수 투여하여 85℃에서 24시간 3차 추출하고 농축한 다음, 다시 순수 정제수를 8배수 투여하여 90℃에서 24시간 4차 추출하여, 진세노사이드 Rb1의 함량이 24mg/g이고, 고형분이 70중량%인 홍삼추출액을 얻었다.Transfer dried red ginseng to the extraction container and administer 8 times of 70% purity alcohol to raw material volume for 24 hours at 75 ℃, extract and concentrate, and then administer 50 times of purity alcohol 8 times to raw material volume for 24 hours at 80 ℃ After the second extraction and concentration, again 30 times the purity 30% alcohol to 8 times the volume of the raw material was extracted three times at 85 ℃ 3 times, and then again purified 8 times as pure purified water to extract 4 times at 90 ℃ 24 hours To obtain a red ginseng extract, the content of ginsenoside Rb 1 is 24mg / g, and the solid content is 70% by weight.
상기 각 추출 단계별로 얻어지는 추출액은 감압농축장치를 이용하여 고형분 함량 60 ~ 70중량%, 잔사 2중량% 미만, 진세노사이드 Rg1 + Rb1 함량 4mg/g~50mg/g 범위로 농축한 추출액으로 하여 추출을 수행하였으며, 각 단계별 추출공정에서 얻어지는 추출액 중의 진세노사이드 Rg3, Rh2의 함량분석은 UVD(Ultra Visible Detector)가 장착된 HPLC(High Performance Liquid Chromatography)로 아래 [표 3] 및 [표 4]에서 나타낸 바와 같은 분석조건과 함량계산식에 의해 분석하였다.The extract obtained in each extraction step is an extract concentrated to a solid content of 60 ~ 70% by weight, less than 2% by weight of residue, ginsenoside Rg 1 + Rb 1 content 4mg / g ~ 50mg / g using a reduced pressure concentrator The extraction was carried out, and the content analysis of ginsenosides Rg 3 , Rh 2 in the extract obtained in each step extraction process was performed by HPLC (High Performance Liquid Chromatography) equipped with UVD (Ultra Visible Detector) [Table 3] and [ Table 4] was analyzed by the analysis conditions and the content calculation formula as shown.
<실시예 1> ≪ Example 1 >
교반이 가능한 500㎖ 크기의 가수분해장치에 상기의 원료 홍삼추출액(Rb1의 함량이 24mg/g, 고형분이 70중량%) 198g을 넣고, 사과산(malic acid) 2g을 첨가하여, 90℃의 항온에서, 48시간 동안 가수분해반응을 진행시킨 후, Rg3와 Rh2가 동시에 강화된 홍삼농축액을 제조하였다. 또한, 사과산 첨가량을 2.5중량% 및 5중량%으로 변화시켜 가수분해반응을 각각 진행하여 Rg3와 Rh2가 동시에 강화된 홍삼농축액을 제조하였으며, 유기산 첨가량 및 반응 시간대별 Rg3와 Rh2의 변화를 조사하고 그 결과는 아래 [표 5]에 나타내었다.198 g of the raw red ginseng extract solution (Rb 1 content of 24 mg / g, solid content of 70% by weight) was added to a 500 ml hydrolyzable device capable of stirring, and 2 g of malic acid was added thereto to maintain a constant temperature of 90 ° C. In, after undergoing a hydrolysis reaction for 48 hours, red ginseng concentrate prepared by simultaneously strengthening Rg 3 and Rh 2 . In addition, by changing the malic acid addition level of 2.5% by weight and 5% by weight progress of the hydrolysis reaction, respectively was prepared for the Red Ginseng extract enhanced Rg 3 and Rh 2 at the same time, changes in the organic acid addition level and reaction time slot Rg 3 and Rh 2 And the results are shown in Table 5 below.
<실시예 2><Example 2>
포도산(tartaric acid)을 사용하는 것을 제외하고는 상기 <실시예 1>과 동일한 방법으로 강화된 홍삼농축액을 제조하였으며, 유기산 첨가량 및 반응 시간대별 Rg3와 Rh2의 변화를 조사하고 그 결과는 아래 [표 6]에 나타내었다.With the exception of using tartaric acid, red ginseng concentrate was prepared in the same manner as in <Example 1>, and the changes of Rg 3 and Rh 2 according to the amount of added organic acid and reaction time were investigated. It is shown in [Table 6] below.
<실시예 3> <Example 3>
호박산(succinic acid)을 사용하는 것을 제외하고는 상기 <실시예 1>과 동일한 방법으로 강화된 홍삼농축액을 제조하였으며, 유기산 첨가량 및 반응 시간대별 Rg3와 Rh2의 변화를 조사하고 그 결과는 아래 [표 7]에 나타내었다.With the exception of using succinic acid, red ginseng concentrate was prepared in the same manner as in <Example 1>, and the changes of Rg 3 and Rh 2 according to the amount of added organic acid and reaction time were investigated. It is shown in [Table 7].
<비교예 1 내지 3><Comparative Examples 1 to 3>
본 발명의 효과를 대비하기 위하여 교반이 가능한 500㎖ 크기의 가수분해장치에 상기의 원료 홍삼추출액(Rb1의 함량이 24mg/g, 고형분이 70%) 190g에 타의 유기산인 구연산(citric acid) 10g을 첨가하고, 온도 90℃의 항온에서, 24시간 동안 가수분해반응을 진행시킨 후 Rg3와 Rh2가 동시에 강화된 홍삼농축액을 제조하였다. 또한, 동일한 반응조건에서 트레오닌(threonine), 알라닌(alanine) 각각을 사용하여 강화된 홍삼농축액을 제조하고, Rg3와 Rh2의 변화에 대하여 비교한 결과를 아래 [표 8]에 나타내었다.In order to prepare for the effect of the present invention in a 500 mL hydrolyzable device capable of stirring, the raw red ginseng extract (Rb 1 content of 24 mg / g, solid content of 70%) in 190 g of other organic acid citric acid (citric acid) 10 g After the addition, at a constant temperature of 90 ℃, proceed with the hydrolysis for 24 hours to prepare a red ginseng concentrate fortified Rg 3 and Rh 2 at the same time. In addition, the red ginseng concentrate prepared by using threonine (threonine), alanine (alanine) under the same reaction conditions, and the results of comparing the changes in Rg 3 and Rh 2 are shown in Table 8 below.
상기 [표 8]에서 나타나는 바와 같이, 본 발명의 실시예에서 사용된 사과산(malic acid), 포도산(tartaric acid) 및 호박산(succinic acid)의 경우 Rg3가 17.1mg/g ~ 21.4mg/g, Rh2가 21.4mg/g ~ 25.7mg/g으로 Rg3 및 Rh2 성분이 동시에 강화되었으나, 반면, 동일한 반응조건(반응온도, 반응시간 및 유기산 첨가량)에서 가수분해반응을 수행한 구연산(citric acid), 트레오닌(threonine) 및 알라닌(alanine)은 Rg3가 8.5mg/g ~ 17.1mg/g으로 강화되었지만 Rh2는 나타나지 않으므로 구연산(citric acid), 트레오닌(threonine) 및 알라닌(alanine)은 Rg3 및 Rh2 성분을 동시에 강화시키는 본 발명의 방법에 적용할 수 없는 것으로 평가되었다.As shown in Table 8, in the case of malic acid, malic acid, tartaric acid, and succinic acid, Rg 3 is in the range of 17.1 mg / g to 21.4 mg / g. , Rh 2 is 21.4mg / g ~ 25.7mg / g, the Rg 3 and Rh 2 components are strengthened at the same time, while citric acid (citric acid) was hydrolyzed under the same reaction conditions (reaction temperature, reaction time and organic acid addition amount) acid, threonine, and alanine are fortified with Rg 3 from 8.5 mg / g to 17.1 mg / g but no Rh 2 , so citric acid, threonine and alanine are Rg 3 3 It was evaluated that the present invention was not applicable to the method of the present invention which simultaneously strengthens the Rh 2 component.
또한, 상기 원료로부터 제조된 홍삼농축액의 진세노사이드 Rg3와 Rh2의 함량이 최소 원료 홍삼추출액에 비하여 10배 이상으로 강화되기 때문에, 본 발명에 따른 유기산 가수분해반응의 원료로 사용하는데 홍삼추출액이 매우 유리한 것으로 평가되었다. In addition, since the content of ginsenosides Rg 3 and Rh 2 of the red ginseng concentrate prepared from the raw material is enhanced by 10 times or more than the minimum raw red ginseng extract, red ginseng extract is used as a raw material of the organic acid hydrolysis reaction according to the present invention. This was rated very advantageous.
A는 진세노사이드 Rg3 및 Rh2의 표준물질에 대한 HPLC 데이터
B는 본 발명에 사용된 원료 홍삼추출액의 Rg3 및 Rh2에 대한 HPLC 데이터
C는 본 발명에서 사과산에 의해 Rg3 및 Rh2가 강화된 홍삼농축액에 대한 HPLC 데이터
D는 본 발명에서 포도산에 의해 Rg3 및 Rh2가 강화된 홍삼농축액에 대한 HPLC 데이터
E는 본 발명에서 호박산에 의한 Rg3 및 Rh2가 강화된 홍삼농축액에 대한 HPLC 데이터A is HPLC data for standards of ginsenosides Rg 3 and Rh 2
B is HPLC data for Rg 3 and Rh 2 of the raw red ginseng extract used in the present invention.
C is HPLC data for red ginseng concentrate enriched in Rg 3 and Rh 2 by malic acid in the present invention.
D is HPLC data for red ginseng concentrate enriched in Rg 3 and Rh 2 by vitric acid in the present invention.
E is HPLC data for red ginseng concentrate enhanced with Rg 3 and Rh 2 by succinic acid in the present invention
Claims (12)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110072609A KR101106487B1 (en) | 2011-07-21 | 2011-07-21 | A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 |
| PCT/KR2012/005032 WO2013012180A2 (en) | 2011-07-21 | 2012-06-26 | Production method for a red ginseng liquid concentrate having boosted levels of ginsenoside rg3 and rh2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110072609A KR101106487B1 (en) | 2011-07-21 | 2011-07-21 | A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101106487B1 true KR101106487B1 (en) | 2012-01-20 |
Family
ID=45614379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110072609A KR101106487B1 (en) | 2011-07-21 | 2011-07-21 | A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101106487B1 (en) |
| WO (1) | WO2013012180A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101508271B1 (en) * | 2013-05-22 | 2015-04-06 | 성신비에스티(주) | Method for manufacturing rice cake and popped rice containing korean red ginseng extract |
| KR101577111B1 (en) * | 2013-08-13 | 2015-12-11 | 주식회사 한국인삼공사 | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction |
| KR101617432B1 (en) | 2013-11-26 | 2016-05-02 | 주식회사 티이바이오스 | Method for preparing Red Ginseng extracts containing abundant ginsenosid Rg3 |
| KR20220095076A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 금산인삼약초산업진흥원 | Red ginseng with enhanced ginsennoside content and manufacturing method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106924276B (en) * | 2017-05-09 | 2021-03-19 | 西北大学 | Ginsenoside composition and application thereof in treating leucoderma |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040034350A (en) * | 2003-05-23 | 2004-04-28 | (주)바이오피아 | Method of the efficient production of vital-G improved immunity and anticancer from ginseng extracts |
| KR20060001834A (en) * | 2005-10-07 | 2006-01-06 | (주)예당바이오 | Preparation method of fermented ginseng or fermented red ginseng using probiotics from kimchi |
| KR20060060643A (en) * | 2006-05-04 | 2006-06-05 | (주)바이오피아 | Increase of functional saponin by acidic treatement and temperature of red ginseng extract |
| KR100992800B1 (en) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | A process for preparing novel processed ginseng or extract thereof showing increased amount of minor ginsenosides |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101052574B1 (en) * | 2008-11-04 | 2011-07-29 | 씨제이제일제당 (주) | Method for preparing an extract fraction with enhanced ginsenosides Rg1 or Rb1 from ginseng |
-
2011
- 2011-07-21 KR KR1020110072609A patent/KR101106487B1/en active IP Right Grant
-
2012
- 2012-06-26 WO PCT/KR2012/005032 patent/WO2013012180A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040034350A (en) * | 2003-05-23 | 2004-04-28 | (주)바이오피아 | Method of the efficient production of vital-G improved immunity and anticancer from ginseng extracts |
| KR20060001834A (en) * | 2005-10-07 | 2006-01-06 | (주)예당바이오 | Preparation method of fermented ginseng or fermented red ginseng using probiotics from kimchi |
| KR20060060643A (en) * | 2006-05-04 | 2006-06-05 | (주)바이오피아 | Increase of functional saponin by acidic treatement and temperature of red ginseng extract |
| KR100992800B1 (en) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | A process for preparing novel processed ginseng or extract thereof showing increased amount of minor ginsenosides |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101508271B1 (en) * | 2013-05-22 | 2015-04-06 | 성신비에스티(주) | Method for manufacturing rice cake and popped rice containing korean red ginseng extract |
| KR101577111B1 (en) * | 2013-08-13 | 2015-12-11 | 주식회사 한국인삼공사 | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction |
| KR101617432B1 (en) | 2013-11-26 | 2016-05-02 | 주식회사 티이바이오스 | Method for preparing Red Ginseng extracts containing abundant ginsenosid Rg3 |
| KR20220095076A (en) * | 2020-12-29 | 2022-07-06 | 재단법인 금산인삼약초산업진흥원 | Red ginseng with enhanced ginsennoside content and manufacturing method thereof |
| KR102597682B1 (en) | 2020-12-29 | 2023-11-02 | 재단법인 금산인삼약초산업진흥원 | Red ginseng with enhanced ginsennoside content and manufacturing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013012180A3 (en) | 2013-03-14 |
| WO2013012180A2 (en) | 2013-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101106487B1 (en) | A process for preparing an red ginseng extract enriched with ginsenoside rg3 and rh2 | |
| CN113150867A (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| KR20050109269A (en) | A ginseng preparation using vinegar and process for thereof | |
| CN102408463A (en) | Extraction method for mogroside | |
| KR20110052940A (en) | A process for preparing an extract fraction enriched with ginsenoside rg3 from ginseng radix | |
| KR101341755B1 (en) | The effective isolation method of panaxadiol saponin fraction from ginseng using pectinase | |
| CN106349324A (en) | Method for extracting and separating maslinic acid from olive leaves | |
| KR100706111B1 (en) | A ginseng preparation using vitamin c and process for thereof | |
| KR101617432B1 (en) | Method for preparing Red Ginseng extracts containing abundant ginsenosid Rg3 | |
| CN104529983A (en) | Method for extracting eriodictyol from water chestnut peel | |
| CN112294830B (en) | American ginseng leaf product rich in rare ginsenoside | |
| CN1053609A (en) | The extraction process of Herba Erigerontis tablet bulk drug | |
| CN103059089B (en) | Method for preparing secondary ginsenoside Rg3 via hydrolyzing primary panaxadiol saponins under catalysis of fresh grape juice | |
| KR20150030012A (en) | High density manufacturing method of effective component from Ginsenosides and Product using the same | |
| JP2008212137A (en) | Method for producing new gisenoside from ginseng by liquid culture of phellinus linteus mycelium utilizing biotransformation method | |
| CN104592185B (en) | Method for extracting quercetin from eleocharis tuberosa peels | |
| KR101095357B1 (en) | Processed Ginseng | |
| CN105712896A (en) | Method for efficiently preparing macamides monomers from Lepidium meyenii | |
| CN113336808A (en) | Glucoside compound extracted and separated from lily, and method and application thereof | |
| KR101102702B1 (en) | The method of reinforcing saponin in ginseng extract | |
| KR101416669B1 (en) | Ginseng prosapogenin high concentration containing ginseng berry preparation using sonication and process for thereof | |
| CN112656828A (en) | Pseudo-ginseng leaf product | |
| KR101308880B1 (en) | Effective manufacturing method of red-ginseng extraction and concentration with mixed microogarnism fermentation | |
| KR101451629B1 (en) | Manufacturing Method for Ginsenoide Rg2 using Sumizyme AC | |
| KR20050097710A (en) | Modified ginsenoside mixture which has selective anti-lung cancer activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20150112 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160111 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20170117 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20180110 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20190110 Year of fee payment: 8 |